Literature DB >> 18540892

One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype.

A R Cid1, M Calabuig, V Cortina, P Casaña, S Haya, A Moret, N Cabrera, J A Aznar.   

Abstract

The discrepancy of the levels of factor VIII activity (FVIII:C) by different assays in some mild and moderate haemophilic A patients has been long known. Specific mutations affecting FVIII:C discrepancies have been described. No consensus exit as to which method most accurately represents the FVIII cofactor function in vivo and which has a better correlation with the haemorrhagic clinical expression. We studied 163 mild A haemophiliacs, and detected discrepancies in 20% of the patients, most of whom presented higher levels of FVIII:C with the one-stage assay. In nine families, the FVIII mutation was found, while three showed mutations not previously described (Leu1978Phe and Ser1791Pro associated with higher levels of FVIII:C by one-stage method; Arg1639His in a patient with low level of FVIII:C by the one-stage, but normal, chromogenic assay). Assessing the level of FVIII:C by different methods could help to learn the possible haemorrhagic expressions of patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18540892     DOI: 10.1111/j.1365-2516.2008.01781.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  13 in total

Review 1.  Genetic sequence analysis of inherited bleeding diseases.

Authors:  Flora Peyvandi; Tom Kunicki; David Lillicrap
Journal:  Blood       Date:  2013-10-11       Impact factor: 22.113

2.  Assessing the Performance of Extended Half-Life Coagulation Factor VIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients.

Authors:  Tarek M Owaidah; Hazzaa A Alzahrani; Nouf S Al-Numair; Abdulmjeed O Alnosair; Amelita M Aguilos; Mahasen Saleh
Journal:  Adv Hematol       Date:  2020-09-09

3.  Specific and global coagulation tests in patients with mild haemophilia A with a double mutation (Glu113Asp, Arg593Cys).

Authors:  Alenka Trampuš Bakija; Maruša Debeljak; Irena Preložnik Zupan; Majda Benedik Dolničar; Jernej Kovač; Janez Jazbec
Journal:  Blood Transfus       Date:  2015-05-15       Impact factor: 3.443

4.  Life-threatening bleeding in a patient with mild hemophilia A and heterozygosity for von Willebrand disease Type 2N.

Authors:  John N Allan; Kenneth D Friedman; Maria T DeSancho
Journal:  Int J Hematol       Date:  2014-09-12       Impact factor: 2.490

5.  Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A.

Authors:  Annette E Bowyer; Joost J Van Veen; Anne C Goodeve; Steve Kitchen; Michael Makris
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

6.  Method validation and clinical utility of chromogenic factor VIII assay compared to one-stage assay.

Authors:  Wilmare Gouws; Elsabie Botha; Adele Visser
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

Review 7.  Haemophilia.

Authors:  Erik Berntorp; Kathelijn Fischer; Daniel P Hart; Maria Elisa Mancuso; David Stephensen; Amy D Shapiro; Victor Blanchette
Journal:  Nat Rev Dis Primers       Date:  2021-06-24       Impact factor: 52.329

8.  A subset of high-titer anti-factor VIII A2 domain antibodies is responsive to treatment with factor VIII.

Authors:  Joshua Eubanks; W Hunter Baldwin; Rebecca Markovitz; Ernest T Parker; Courtney Cox; Christine L Kempton; Shannon L Meeks
Journal:  Blood       Date:  2016-01-29       Impact factor: 22.113

Review 9.  Clinical and laboratory approaches to hemophilia a.

Authors:  Hassan Mansouritorghabeh
Journal:  Iran J Med Sci       Date:  2015-05

10.  Cross-reacting Material-positive Hemophilia A Diagnosed in a Patient with a Spontaneous Thigh Hemorrhage.

Authors:  Tatsuya Saito; Jyunichi Mukae; Yosuke Nakamura; Hiroshi Inaba; Keiji Nogami; Takatoshi Koyama; Katsuyuki Fukutake; Koh Yamamoto
Journal:  Intern Med       Date:  2017-07-01       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.